<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540137</url>
  </required_header>
  <id_info>
    <org_study_id>Eudra-CT 2007-002405-47</org_study_id>
    <nct_id>NCT00540137</nct_id>
  </id_info>
  <brief_title>The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects</brief_title>
  <official_title>A Randomised Prospective Study Assessing Changes in Neurocognitive Function, Using a Computerised Test Battery, in Treatment Naïve HIV-1 Positive Subjects Commencing Two Different Antiretroviral Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the possibility of an association between changes
      in neurocognitive function, as measured by a computerised test battery, and the use of two
      different highly active antiretroviral therapy (HAART) regimens in treatment naïve HIV-1
      infected subjects commencing antiretroviral therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess changes in simple reaction time as measured by a computerised test battery</measure>
    <time_frame>over study period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>NRTIs plus NNRTI arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nevirapine 400 mg once daily (after 12 weeks induction)with a nucleoside backbone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRTIs plus PI arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atazanavir 300 mg once daily, ritonavir 100 mg once daily with a nucleoside backbone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine</intervention_name>
    <description>400mg once daily</description>
    <arm_group_label>NRTIs plus NNRTI arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir/ritonavir</intervention_name>
    <description>atazanavir 300 mg once daily ritonavir 100 mg once daily</description>
    <arm_group_label>NRTIs plus PI arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected males or females

          -  Signed informed consent

          -  No previous antiretroviral treatment

          -  Males with CD4+ lymphocyte count &lt; 400 cells/ųL and females with CD4+ lymphocyte count
             &lt; 250 cells/ųL

          -  Susceptible to all currently licensed nucleoside reverse transcriptase inhibitors
             (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease
             inhibitors (PIs)

        Exclusion Criteria:

          -  Existing neurological disease

          -  Hepatitis B or hepatitis C co-infection

          -  Current history of major depression or psychosis

          -  Recent head injury

          -  Current alcohol abuse or drug dependence

          -  Active opportunistic infection or significant co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Winston</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2007</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>Neurocognitive function</keyword>
  <keyword>Magnetic resonance spectroscopy</keyword>
  <keyword>HIV disease</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

